KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Total Non-Current Liabilities: 2018-2023

Historic Total Non-Current Liabilities for Castle Biosciences (CSTL) over the last 5 years, with Dec 2023 value amounting to $62.0 million.

  • Castle Biosciences' Total Non-Current Liabilities was N/A to $94.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.2 million, marking a year-over-year change of. This contributed to the annual value of $62.0 million for FY2023, which is 29.02% up from last year.
  • Castle Biosciences' Total Non-Current Liabilities amounted to $62.0 million in FY2023, which was up 29.02% from $48.1 million recorded in FY2022.
  • Castle Biosciences' 5-year Total Non-Current Liabilities high stood at $62.0 million for FY2023, and its period low was $22.6 million during FY2020.
  • Over the past 3 years, Castle Biosciences' median Total Non-Current Liabilities value was $48.1 million (recorded in 2022), while the average stood at $47.6 million.
  • Data for Castle Biosciences' Total Non-Current Liabilities shows a peak YoY surged of 47.76% (in 2022) over the last 5 years.
  • Over the past 4 years, Castle Biosciences' Total Non-Current Liabilities (Yearly) stood at $22.6 million in 2020, then spiked by 43.93% to $32.5 million in 2021, then spiked by 47.76% to $48.1 million in 2022, then grew by 29.02% to $62.0 million in 2023.